KR100997998B1 - Korean intestine-derived microorganisms having saponin-biotransforming activity and processes for preparing fermented ginseng using the same - Google Patents
Korean intestine-derived microorganisms having saponin-biotransforming activity and processes for preparing fermented ginseng using the same Download PDFInfo
- Publication number
- KR100997998B1 KR100997998B1 KR1020090032163A KR20090032163A KR100997998B1 KR 100997998 B1 KR100997998 B1 KR 100997998B1 KR 1020090032163 A KR1020090032163 A KR 1020090032163A KR 20090032163 A KR20090032163 A KR 20090032163A KR 100997998 B1 KR100997998 B1 KR 100997998B1
- Authority
- KR
- South Korea
- Prior art keywords
- ginseng
- ginsenoside
- saponin
- strain
- korean
- Prior art date
Links
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 113
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 109
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 103
- 241000208340 Araliaceae Species 0.000 title claims abstract 11
- 238000000034 method Methods 0.000 title claims description 19
- 244000005700 microbiome Species 0.000 title description 29
- 230000000694 effects Effects 0.000 title description 7
- 210000000936 intestine Anatomy 0.000 title description 4
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 23
- 238000000855 fermentation Methods 0.000 claims abstract description 22
- 230000004151 fermentation Effects 0.000 claims abstract description 22
- 229930182490 saponin Natural products 0.000 claims abstract description 16
- 150000007949 saponins Chemical class 0.000 claims abstract description 15
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 13
- 230000032683 aging Effects 0.000 claims description 18
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 17
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 17
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 17
- 241000186612 Lactobacillus sakei Species 0.000 claims description 16
- 239000006228 supernatant Substances 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 3
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 abstract description 30
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 abstract description 18
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 241000186660 Lactobacillus Species 0.000 abstract description 8
- 229940039696 lactobacillus Drugs 0.000 abstract description 8
- 240000004371 Panax ginseng Species 0.000 description 103
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 20
- 239000000047 product Substances 0.000 description 14
- 235000017709 saponins Nutrition 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 239000004310 lactic acid Substances 0.000 description 10
- 235000014655 lactic acid Nutrition 0.000 description 10
- 108020004465 16S ribosomal RNA Proteins 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 229930182494 ginsenoside Natural products 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- KWDWBAISZWOAHD-UHFFFAOYSA-N Ginsenoside Rk1 Natural products CC(C)=CCCC(=C)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O KWDWBAISZWOAHD-UHFFFAOYSA-N 0.000 description 6
- 240000005373 Panax quinquefolius Species 0.000 description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 6
- 235000020710 ginseng extract Nutrition 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 5
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 5
- 235000021109 kimchi Nutrition 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 229940089161 ginsenoside Drugs 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000010306 acid treatment Methods 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 description 2
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 description 2
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 2
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 description 2
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000168720 Panax japonicus Species 0.000 description 2
- 235000003174 Panax japonicus Nutrition 0.000 description 2
- 241000180649 Panax notoginseng Species 0.000 description 2
- 235000003143 Panax notoginseng Nutrition 0.000 description 2
- 244000131316 Panax pseudoginseng Species 0.000 description 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 2
- 241001527087 Panax vietnamensis Species 0.000 description 2
- 235000017726 Panax vietnamensis Nutrition 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- CNHRRMQBWQJRPN-UHFFFAOYSA-N chikusetsusaponin LM5 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C1O CNHRRMQBWQJRPN-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- XJRPTMORGOIMMI-UHFFFAOYSA-N ethyl 2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C(F)(F)F XJRPTMORGOIMMI-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical class C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 2
- NODILNFGTFIURN-GZPRDHCNSA-N ginsenoside Rb2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-GZPRDHCNSA-N 0.000 description 2
- PFSIGTQOILYIIU-UHFFFAOYSA-N ginsenoside Rb3 Natural products CC(=CCCC(C)(O)C1CCC2(C)C3CCC4C(C)(C)C(CCC4(C)C3CC(OC5OC(COC6OCC(O)C(O)C6O)C(O)C(O)C5O)C12C)OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C PFSIGTQOILYIIU-UHFFFAOYSA-N 0.000 description 2
- JDCPEKQWFDWQLI-LUQKBWBOSA-N ginsenoside Rc Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O JDCPEKQWFDWQLI-LUQKBWBOSA-N 0.000 description 2
- SPFXZQZPHXUJSR-UHFFFAOYSA-N ginsenoside-Rc Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1OC2OC(CO)C(O)C2O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C SPFXZQZPHXUJSR-UHFFFAOYSA-N 0.000 description 2
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- SHCBCKBYTHZQGZ-CJPZEJHVSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-CJPZEJHVSA-N 0.000 description 2
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 230000002883 vasorelaxation effect Effects 0.000 description 2
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 1
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- VBUYCZFBVCCYFD-JJYYJPOSSA-N 2-dehydro-D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)C(O)=O VBUYCZFBVCCYFD-JJYYJPOSSA-N 0.000 description 1
- GHWSMQHJFMAATF-DSHMRAQASA-N 20(S)-protopanaxadiol Natural products CC(=CCC[C@@](O)(CO)[C@H]1CC[C@]2(C)[C@@H]1CC[C@H]3[C@@]2(C)CC[C@H]4C(C)(C)[C@@H](O)CC[C@]34CO)C GHWSMQHJFMAATF-DSHMRAQASA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N D-Arabitol Natural products OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N D-Cellobiose Natural products OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- SHZGCJCMOBCMKK-SVZMEOIVSA-N D-fucopyranose Chemical compound C[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O SHZGCJCMOBCMKK-SVZMEOIVSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 1
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- NJUXRKMKOFXMRX-RNCAKNGISA-N Ginsenoside Rg5 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4C(/C)=C/CC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NJUXRKMKOFXMRX-RNCAKNGISA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- HEBKCHPVOIAQTA-IMJSIDKUSA-N L-arabinitol Chemical compound OC[C@H](O)C(O)[C@@H](O)CO HEBKCHPVOIAQTA-IMJSIDKUSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 description 1
- 241000186715 Lactobacillus alimentarius Species 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 241001627205 Leuconostoc sp. Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- DKXNBNKWCZZMJT-UHFFFAOYSA-N O4-alpha-D-Mannopyranosyl-D-mannose Natural products O=CC(O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O DKXNBNKWCZZMJT-UHFFFAOYSA-N 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- 235000007189 Oryza longistaminata Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000604136 Pediococcus sp. Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 1
- PYMYPHUHKUWMLA-WISUUJSJSA-N aldehydo-L-xylose Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WISUUJSJSA-N 0.000 description 1
- 229930195726 aldehydo-L-xylose Natural products 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940089837 amygdalin Drugs 0.000 description 1
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- CJFGBCWGOQRURQ-JFJIKBJRSA-N ginsenoside Mc Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O CJFGBCWGOQRURQ-JFJIKBJRSA-N 0.000 description 1
- CJFGBCWGOQRURQ-UHFFFAOYSA-N ginsenoside Mc Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C1O CJFGBCWGOQRURQ-UHFFFAOYSA-N 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical class O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- NJUXRKMKOFXMRX-AXUZFSSLSA-N ginsenoside Rg5 Natural products CC(=CCC=C(C)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]3[C@@]4(C)CC[C@@H](O[C@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(C)(C)[C@@H]4CC[C@@]23C)C NJUXRKMKOFXMRX-AXUZFSSLSA-N 0.000 description 1
- NJUXRKMKOFXMRX-UHFFFAOYSA-N ginsenoside Rz1 Natural products CC(C)=CCC=C(C)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NJUXRKMKOFXMRX-UHFFFAOYSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ABXHMFFYSA-N melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-ABXHMFFYSA-N 0.000 description 1
- 238000010309 melting process Methods 0.000 description 1
- HOVAGTYPODGVJG-ZFYZTMLRSA-N methyl alpha-D-glucopyranoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-ZFYZTMLRSA-N 0.000 description 1
- HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 1
- ZBDGHWFPLXXWRD-JGWLITMVSA-N methyl beta-D-xylopyranoside Chemical compound CO[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O ZBDGHWFPLXXWRD-JGWLITMVSA-N 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- GSFHMOMWXNDPMM-YMDUGQBDSA-M potassium;(2r,3s,4s)-2,3,4,6-tetrahydroxy-5-oxohexanoate Chemical compound [K+].OCC(=O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O GSFHMOMWXNDPMM-YMDUGQBDSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- -1 triol saponins Chemical class 0.000 description 1
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/179—Sakei
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 사포닌 생물전환능을 갖는 신규의 락토바실러스속 균주 및 이를 이용한 인삼 발효물의 제조방법을 제공한다. 본 발명에 따라 새롭게 분리된 상기 균주를 수삼, 백삼, 홍삼 등의 인삼에 접종하고 배양할 경우, 진세노사이드 Rg3 및 △20-진세노나이드 Rg3의 함량이 높은 인삼 발효물을 얻을 수 있다.The present invention provides a novel Lactobacillus strain having a saponin bioconversion capacity and a method for producing a ginseng fermented product using the same. When the strain is newly isolated according to the present invention inoculated with ginseng such as ginseng, white ginseng, red ginseng and cultured, ginseng fermentation products having a high content of ginsenoside Rg3 and Δ20-ginsenoide Rg3 can be obtained.
인삼, 홍삼, 진세노나이드 Rg3 Ginseng, Red Ginseng, Ginsenide Rg3
Description
본 발명은 한국인의 장에서 유래한 사포닌 생물전환능을 갖는 신규의 락토바실러스속 균주 및 이를 이용한 인삼 발효물의 제조방법에 관한 것이다.The present invention relates to a novel Lactobacillus strain having a saponin bioconversion ability derived from Korean intestine and a method for preparing ginseng fermented product using the same.
인삼은 식물 분류학상 오가과 인삼속에 속하는 다년생 숙근초로서 지구상에 약 11종이 알려져 있으며, 대표적인 종으로는 고려 인삼(Panax ginseng C. A. Meyer), 미국삼(Panax quinquefolium L.), 전칠삼(Panax notoginseng F. H. Chen), 죽절삼(Panax japonicus C. A. Meyer) 등이 있다. 고려 인삼(Panax ginseng C. A. Meyer)은 아시아 극동 지역(북위 33 ∼ 48°, 한국, 북만주, 러시아 일부)에 자생하며, 약효가 매우 우수하다. 미국삼(Panax quinquefolium L.)은 미국, 캐나다에 자생 및 재배되며, 전칠삼(Panax notoginseng F. H. Chen)은 중국 운남성 동남부로부터 광서성 서남부 지역에서 야생 또는 재배된다. 또한 죽절삼(Panax japonicus C. A. Meyer)은 일본, 중국 서남부, 네팔에 이르기까지 분포한다Ginseng has approximately 11 species known on Earth as a perennial belonging to the genus sukgeuncho haksang ohgagwa ginseng plant classification, typical species include Korean ginseng (Panax ginseng CA Meyer), American ginseng (Panax quinquefolium L.), jeonchilsam (Panax notoginseng FH Chen), Panax japonicus CA Meyer. Korean ginseng ( Panax ginseng CA Meyer) is native to the Far East of Asia (33-48 ° N, Korea, Northern Manchuria, and parts of Russia), and has excellent medicinal effects. American ginseng ( Panax quinquefolium L.) grows and grows in the United States and Canada. Panax notoginseng FH Chen is grown or grown in southwestern Guangxi from southeastern Yunnan Province. Also, Panax japonicus CA Meyer is distributed in Japan, southwest China and Nepal.
인삼의 주요성분 및 약리작용에 관한 연구가 발표됨에 따라, 자연 건강식품으로 각광을 받고 있으며, 그 수요도 점차 신장 되고 있고, 경제성장과 생활수준의 향상으로 더욱 가속화되어 대중적 자연건강식품으로 널리 애용되고 있다. 또한 인삼은 주로 한국 등 아시아 국가에서 생약의 형태로 정신 의학적, 신경계의 질병 및 당뇨병 등 여러 가지 질병에 대해 사용되어 왔으며, 상기 인삼의 주요 성분인 사포닌은 강장, 강정, 진정, 조혈 및 항고혈압 등에 효과를 나타내는 것으로 보고되고 있다.As research on the major ingredients and pharmacological effects of ginseng has been published, it has been spotlighted as a natural health food, its demand is gradually increasing, and it has been accelerated by economic growth and improvement of living standard, and widely used as a popular natural health food. It is becoming. In addition, ginseng has been used for various diseases such as psychiatry, nervous system diseases and diabetes in the form of herbal medicine mainly in Asian countries such as Korea, and saponins, the main components of the ginseng, are tonic, tonic, soothing, hematopoietic and antihypertensive It is reported to have an effect.
일반적으로 인삼은 재배하여 채취한 그대로의 수삼, 수삼을 상온에서 건조시킨 백삼 또는 수삼을 정제수로 세척한 다음 약 98 ∼ 100℃ 에서 수증기로 증삼 처리하여 제조되는 홍삼의 형태로 이용되고 있다. 이 중에서 특히 홍삼은 백삼보다 훨씬 약효가 강한 것으로 알려져 있다. In general, ginseng is used in the form of red ginseng, which is produced by washing ginseng as it is grown and harvested, dried white ginseng or fresh ginseng at room temperature, and then steamed with steam at about 98 to 100 ° C. Of these, red ginseng is known to be much stronger than white ginseng.
최근에는 이러한 인삼의 약효성분이 인체 내로 용이하게 흡수되도록 하며, 인삼에 극미량으로 존재하는 성분들을 강화시키는 방법으로서 인삼을 장내 미생물 또는 유산균을 이용하여 발효하거나 및 효소를 처리하는 방법 등이 사용되고 있다.Recently, the active ingredients of ginseng are easily absorbed into the human body, and as a method of reinforcing the components present in ginseng in trace amounts, the method of fermenting ginseng using intestinal microorganisms or lactic acid bacteria or treating enzymes is used.
대한민국 특허출원 제1980-4291호는 인삼의 고유 향기 성분을 분리한 인삼 잔박을 효소 분해하여 유기태 질소 농도가 0.2 - 0.8 %, 포도당의 생성 함유량이 유산균 발효에 적합한 3% 이상이 되었을 때 유기산으로 pH 3.8 - 4.8로 조절한 후 불용성 고분자 단백질과 섬유질을 제거하고 용출액에 유산균을 배양시킨 다음 이에 인삼 고유의 향기 성분을 첨가하는 공정을 포함하는 유산균 인삼 음료의 제조방법을 개시하고 있다.Republic of Korea Patent Application No. 1980-4291 enzymatically decomposes ginseng residues from the intrinsic fragrance of ginseng to produce organic pH when the organic nitrogen concentration is 0.2-0.8% and the glucose content is 3% or more suitable for lactic acid bacteria fermentation. Disclosed is a method for preparing a lactic acid bacteria ginseng beverage, comprising the step of adjusting the concentration of 3.8 to 4.8 to remove insoluble polymer protein and fiber, culturing the lactic acid bacteria in the eluate, and then adding a flavor component unique to ginseng.
대한민국 특허공개 제1997-061909호에서는 인삼사포닌의 장내 세균 대사물로서, 프로토파낙사다이올계 사포닌인 진세노사이드 Rb1, 진세노사이드 Rb2, 진세노사이드 Rc 및 진세노사이드 Rd의 대사 생성물로서 화합물 K, 화합물 Y 및 진세노사이드 Mc로 명명한 [20-0-[a-L-아라비노푸라노실(16)-β-D-글루코피라노실]-20(S)-프로토파낙사다이올]을, 또 프로토파낙사 트라이올계 사포닌인 진세노사이드 Rg1 및 진세노사이드-Re의 대사 생성물로서 20(S)-프로토파낙사트라이올을 단리 동정한 것을 개시한 바 있다.Korean Patent Publication No. 1997-061909 discloses a compound K as an intestinal bacterial metabolite of ginseng saponin and a metabolite of ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rc, and ginsenoside Rd, which are protofaanaxadiol-based saponins. , [20-0- [aL-arabinofuranosyl (16) -β-D-glucopyranosyl] -20 (S) -protopanaxadiol] designated as compound Y and ginsenoside Mc; It has been disclosed that 20 (S) -protopanaxatriol was isolated and identified as a metabolite of ginsenoside Rg1 and ginsenoside-Re, which are protoanax triol saponins.
또한, 대한민국 특허등록 제479,803호, 제497,895호, 제517,899호, 제618,171호 등은 인삼 또는 인삼 추출액을 유산균 또는 장내 세균으로 발효시켜, 20-0-β-D-글루코피라노실-20(S)-프로토파낙사디올(화합물 K), 진세노사이드 F, 20(S)-프로토파낙사디올, 20(S)-프로토파낙사트리올 등의 함량이 높은 발효 인삼(즉, 인삼 추출물) 및 그의 제조방법을 개시한 바 있다.In addition, Korean Patent Registration Nos. 479,803, 497,895, 517,899, 618,171, etc., ferment the ginseng or ginseng extract with lactic acid bacteria or enteric bacteria, 20-0-β-D-glucopyranosyl-20 (S Fermented ginseng (i.e. ginseng extract) with high content of) -protopanaxadiol (Compound K), ginsenoside F, 20 (S) -protopanaxadiol, 20 (S) -protopanaxatriol, and the like, and The preparation method thereof has been disclosed.
한편, 대한민국 특허등록 제228,510호는 인삼을 110 - 180℃의 온도에서 0.5 - 20 시간 동안 가열처리하고, 수득된 가공인삼을 알콜, 헥산, 에테르, 디클로로메탄, 클로로포름, 에틸아세테이트 및 그들의 혼합용매로 이루어진 군으로부터 선택되는 유기용매로 추출한 후에 추출물을 크로마토그라피 처리하고 진세노사이드 Rg3 및/또는 Rg5를 분리 수득하는 단계를 포함하는 진세노사이드 Rg3 및/또는 Rg5의 제조방법을 개시한 바 있다. 대한민국 특허등록 제228,510호에 따르면, 상기 진세노사이드 Rg3 및/또는 Rg5는 우수한 혈관이완 효과를 갖는 사포닌의 대사산물이다. Meanwhile, Korean Patent Registration No. 228,510 heats ginseng at a temperature of 110-180 ° C. for 0.5-20 hours, and processes the obtained ginseng with alcohol, hexane, ether, dichloromethane, chloroform, ethyl acetate, and mixed solvents thereof. After the extraction with an organic solvent selected from the group consisting of chromatographed the extract and ginsenosides Rg3 and / or Rg5 comprising a step of separating and obtaining a method for preparing ginsenosides Rg3 and / or Rg5. According to Korean Patent Registration No. 228,510, the ginsenoside Rg3 and / or Rg5 is a metabolite of saponin having an excellent vasorelaxant effect.
상기 진세노사이드 Rg3 및 △20-진세노사이드 Rg3는 우수한 혈관이완 효과 뿐만 아니라 항종양 및 항암효과가 우수한 것으로 알려져 있다(Kim et al., Eur. J. Pharmacol. 1999, 367(1):51-57; Kim et al., Arch. Pharm. Res. 2004, 27(4):429-435; Li X. et al., Sichuan Da Xue Xue Bao Yi Xue Ban. 2005, 36(2):217-220).The ginsenoside Rg3 and Δ20-ginsenoside Rg3 are known to have excellent anti-tumor and anticancer effects as well as excellent vasodilating effect (Kim et al., Eur. J. Pharmacol. 1999, 367 (1): 51 -57; Kim et al., Arch. Pharm. Res. 2004, 27 (4): 429-435; Li X. et al., Sichuan Da Xue Xue Bao Yi Xue Ban. 2005, 36 (2): 217- 220).
그러나, 대한민국 특허등록 제228,510호에 개시된 바에 따라, 진세노사이드 Rg3 및 20-진세노사이드 Rg3의 함량이 높은 인삼 추출물을 제조하는 경우, 열처리 과정에서 생성되는 HMF(Hydroxylmethylfurfual) 등과 같은 발암물질의 생성을 피할 수 없으며, 열 및/또는 산처리 공정에 따라 필연적으로 중화 공정을 거쳐야 하고, 추출정제 과정을 별도로 수행하여야 하므로 직접 식품으로서의 사용이 곤란하다.However, as disclosed in Korean Patent Registration No. 228,510, when preparing ginseng extracts having a high content of ginsenoside Rg3 and 20-ginsenoside Rg3, generation of carcinogens such as HMF (Hydroxylmethylfurfual) generated during heat treatment Inevitably, it is difficult to use directly as a food because it must inevitably undergo a neutralization process according to a heat and / or acid treatment process, and an extraction and purification process must be performed separately.
또한, 대한민국 특허등록 제479,803호, 제497,895호, 제517,899호, 제618,171호 등에 개시된 바에 따라 유산균 또는 장내 세균으로 인삼을 발효시켜 인삼 추출물을 제조하는 경우, 얻어지는 인삼 추출물 중에 진세노사이드 Rg3 및 △20-진세노사이드 Rg3의 함량이 매우 낮아 혈관이완 효과, 항종양, 및 항암효과를 기대하기가 곤란하다. In addition, when ginseng extract is prepared by fermenting ginseng with lactic acid bacteria or enteric bacteria as disclosed in Korean Patent Registration Nos. 479,803, 497,895, 517,899, 618,171, Ginsenoside Rg3 and △ The content of 20-ginsenoside Rg3 is very low, making it difficult to expect vasodilation, antitumor, and anticancer effects.
또한, 대한민국 특허등록 제789,678호, 제856,790호 및 제866,504호는 신규 미생물 즉, 페디오코거스 속(Pediococcus Sp.) 균주 및 루코노스톡 속(Leuconostoc Sp.) 균주, 락토바실러스 알리멘타리우스(Lactobacillus alimentarius) M-2 균주(KCTC 11054 BP), 류코노스톡 멘센테로이드스(Leuconostoc mensenteroides) M-3 균주(KCTC 11055 BP), 락토바실러스 브레비스(Lactobacillus brevis) M2 균주(KCTC11390BP) 및 락토바실러스 플란타럼(Lactobacillus plantarum) P2 균 주(KCTC11391BP) 등으로 인삼을 발효시켜 진세노사이드 Rg3 의 함량이 높은 발효 인삼의 제조방법을 개시한 바 있다. 그러나, 상기 종래의 제조방법에 따라 인삼을 발효시키더라도, 진세노사이드 Rg3 의 함량이 최대 약 10% 정도로 낮기 때문에, 여전히 만족스럽지 못하다. In addition, the Republic of Korea Patent No. 789 678, 1 - 856 790 and No. 866 504 discloses a novel microorganism that is, Phedi OKO Gus in (Pediococcus Sp.) Strains and Lu Pocono stock in (Leuconostoc Sp.) Strain, Lactobacillus Ali menta Julius (Lactobacillus alimentarius ) M-2 strain (KCTC 11054 BP), Leuconostoc mensenteroides M-3 strain (KCTC 11055 BP), Lactobacillus brevis M2 strain (KCTC11390BP) and Lactobacillus plantarta A method of preparing fermented ginseng with high content of ginsenoside Rg3 has been disclosed by fermenting ginseng with rum ( Lactobacillus plantarum ) P2 strain (KCTC11391BP). However, even if the ginseng is fermented according to the conventional manufacturing method, because the content of ginsenoside Rg3 is as low as up to about 10%, it is still not satisfactory.
본 발명자들은 혈관이완 효과, 항종양, 및 항암효과가 우수한 것으로 알려져 있는 진세노사이드 Rg3 및 △20-진세노나이드 Rg3의 함량이 높은 인삼 발효물을 생성할 수 있는 미생물을 광범위하게 탐색하였다. 그 결과, 전국 각지에서 수집한 분변 및 김치액으로부터 인삼 발효 활성을 가지는 수십종의 미생물을 분리하였으며, 이 중 락토바실러스(Lactobacillus) 속에 속하는 2 종의 균주가 월등히 높은 사포닌 생물전환능을 가짐으로써, 진세노사이드 Rg3 및 △20-진세노나이드 Rg3의 함량이 높은 인삼 발효물을 제조할 수 있다는 것을 발견하였다. The present inventors have extensively searched for microorganisms capable of producing ginseng fermentation products having high content of ginsenoside Rg3 and Δ20-ginsenoide Rg3, which are known to be excellent in vasorelaxation, antitumor, and anticancer effects. As a result, dozens of microorganisms having ginseng fermentation activity were isolated from feces and kimchi liquid collected from all over the country. Among them, two strains belonging to the genus Lactobacillus have a significantly higher saponin bioconversion capacity. It has been found that ginseng fermentation with high content of ginsenoside Rg3 and Δ20-ginsenoide Rg3 can be prepared.
따라서, 본 발명은 사포닌 생물전환능을 갖는 신규의 락토바실러스 속 미생물을 제공하는 것을 목적으로 한다.Therefore, an object of the present invention is to provide a novel Lactobacillus genus microorganism having a saponin bioconversion ability.
또한, 본 발명은 상기 미생물을 이용한 인삼 발효물의 제조방법을 제공하는 것을 목적으로 한다.In addition, an object of the present invention is to provide a method for producing a ginseng fermented product using the microorganism.
본 발명의 일 태양에 따라, 사포닌 생물전환능을 갖는 락토바실러스 플란타럼(Lactobacillus plantarum) KFCC11434P 또는 락토바실러스 사케이(Lactobacillus sakei) KFCC11435P가 제공된다.According to one aspect of the present invention, Lactobacillus plantarum KFCC11434P or Lactobacillus sakei KFCC11435P having saponin bioconversion ability is provided.
본 발명의 다른 태양에 따라, 락토바실러스 플란타럼(Lactobacillus plantarum) KFCC11434P 및 락토바실러스 사케이(Lactobacillus sakei) KFCC11435P로 이루어진 군으로부터 선택된 적어도 하나의 균주를 인삼에 접종하고, 배양하는 단계를 포함하는 인삼 발효물의 제조방법이 제공된다.According to another aspect of the present invention, ginseng comprising inoculating and culturing ginseng with at least one strain selected from the group consisting of Lactobacillus plantarum KFCC11434P and Lactobacillus sakei KFCC11435P. A method for producing a fermentation product is provided.
상기 인삼 발효물의 제조방법에 있어서, 상기 인삼은 수삼, 백삼, 또는 홍삼일 수 있다. 또한, 상기 인삼 발효물의 제조방법은 상기 배양 후 얻어진 배양액을 80 ∼ 95 ℃에서 12 ∼ 48 시간 동안 숙성시키는 단계("숙성 단계")를 추가로 포함할 수 있다. 또한, 상기 인삼 발효물의 제조방법은 상기 숙성 단계를 수행하여 얻어진 숙성액 또는 상기 숙성액을 원심분리하여 취한 상등액을 농축 또는 동결건조하는 단계를 추가로 포함할 수 있다.In the production method of the ginseng fermentation, the ginseng may be ginseng, white ginseng, or red ginseng. In addition, the method of producing the ginseng fermentation may further include the step of aging the culture solution obtained after the culture at 80 to 95 ℃ for 12 to 48 hours ("aging step"). In addition, the manufacturing method of the ginseng fermentation may further comprise the step of concentrating or lyophilizing the aging liquid obtained by performing the aging step or the supernatant taken by centrifuging the aging liquid.
본 발명에 의해 새롭게 분리된 락토바실러스속 미생물 즉, 락토바실러스 플란타럼(Lactobacillus plantarum) KFCC11434P 및 락토바실러스 사케이(Lactobacillus sakei) KFCC11435P는 우수한 사포닌 생물전환능을 갖는다. 특히, 상기 미생물을 수삼, 백삼, 홍삼 등의 인삼에 접종하고 배양할 경우, 진세노사이드 Rg3 및 △20-진세노나이드 Rg3의 함량이 높은 인삼 발효물을 얻을 수 있다. Lactobacillus plantarum KFCC11434P and Lactobacillus sakei KFCC11435P newly isolated by the present invention have excellent saponin bioconversion ability. In particular, when the microorganism is inoculated with ginseng such as ginseng, white ginseng, red ginseng, and cultured, ginseng fermentation products having a high content of ginsenoside Rg3 and Δ20-ginsenoide Rg3 can be obtained.
본 명세서에서 "인삼 발효물"이라 함은 수삼, 백삼, 홍삼 등의 인삼에 미생물, 특히 락토바실러스 플란타럼(Lactobacillus plantarum) KFCC11434P 및/또는 락토바실러스 사케이(Lactobacillus sakei) KFCC11435P을 접종하고, 배양하여 얻어진 생성물을 말하며, '발효 인삼' 등으로 지칭되기도 한다."Ginseng fermented product" as used herein is inoculated with microorganisms, especially Lactobacillus plantarum KFCC11434P and / or Lactobacillus sakei KFCC11435P to ginseng, such as ginseng, white ginseng, red ginseng, and cultured It refers to a product obtained by, and may also be referred to as 'fermented ginseng' and the like.
본 발명은 사포닌 생물전환능을 갖는 미생물로서, 우수한 진세노사이드 Rg3 및 △20-진세노나이드 Rg3 생성능을 갖는 신규의 미생물 즉, 락토바실러스 플란타 럼(Lactobacillus plantarum) KFCC11434P 또는 락토바실러스 사케이(Lactobacillus sakei) KFCC11435P를 제공한다.The present invention is a microorganism having a saponin bioconversion ability, a novel microorganism having excellent ginsenoside Rg3 and Δ20-ginsenoide Rg3 generating ability, that is, Lactobacillus plantarum KFCC11434P or Lactobacillus Sakii ( Lactobacillus) sakei ) to provide KFCC11435P.
본 발명자들은 전국 각지에서 분변 및 김치액을 수집하였으며, 유산균 분리용 배지(MRS-BCP 배지)를 사용하여 단일 집락을 형성하는 균주들을 분리하였다. 얻어진 균주들을 홍삼 농축액에 가하여 대사 활성을 측정하였으며, 발효 활성을 갖는 수십종의 미생물을 분리하였다. 얻어진 미생물들로부터 사포닌 생물전환능, 특히 진세노사이드 Rg3 및 △20-진세노나이드 Rg3 생성능이 특히 높은 미생물 2종을 선별하였다. 분리된 2종의 미생물의 16S rRNA 유전자 서열을 분석한 결과, 각각 서열번호 1 및 2의 염기서열을 갖는다는 것이 밝혀졌고, 이를 BLAST를 사용하여 상동성을 비교하고 균주의 특성을 분석한 결과, 각각 락토바실러스 플란타럼(Lactobacillus plantarum) 및 락토바실러스 사케이에 속하는 새로운 균주로 판명되었다. 상기 2종의 균주 즉, 락토바실러스 플란타럼(Lactobacillus plantarum) CKDHC 0801 및 락토바실러스 사케이(Lactobacillus sakei) CKDHC 0802 를 한국미생물보존센터에 2008년 12월 18일자로 기탁하고, 기탁번호 KFCC 11434P 및 KFCC 11435P를 부여받았다.The present inventors collected fecal and kimchi solution from all over the country, and isolated strains forming a single colony using lactic acid bacteria separation medium (MRS-BCP medium). The obtained strains were added to the red ginseng concentrate to measure metabolic activity, and dozens of microorganisms having fermentation activity were isolated. From the obtained microorganisms, two kinds of microorganisms having particularly high saponin bioconversion ability, particularly ginsenoside Rg3 and Δ20-ginsenoide Rg3 generating ability, were selected. As a result of analyzing 16S rRNA gene sequences of two isolated microorganisms, it was found that they had nucleotide sequences of SEQ ID NOs: 1 and 2, respectively, and compared the homology using BLAST, and analyzed the characteristics of the strains. It was found to be a new strain belonging to Lactobacillus plantarum and Lactobacillus sakei , respectively. The two strains, Lactobacillus plantarum CKDHC 0801 and Lactobacillus sakei CKDHC 0802, were deposited to the Korea Microorganism Conservation Center on Dec. 18, 2008, and deposited with KFCC 11434P and KFCC 11435P was granted.
본 발명은 또한 락토바실러스 플란타럼(Lactobacillus plantarum) KFCC11434P 및 락토바실러스 사케이(Lactobacillus sakei) KFCC11435P로 이루어진 군으로부터 선택된 적어도 하나의 균주를 인삼에 접종하고, 배양하는 단계를 포함하는 인삼 발효물의 제조방법을 제공한다. 상기한 바와 같이, 본 발명에 의해 새롭게 분리된 락토바실러스 플란타럼(Lactobacillus plantarum) KFCC11434P 및 락토바 실러스 사케이(Lactobacillus sakei) KFCC11435P는 우수한 사포닌 생물전환능을 가지며, 특히, 이를 이용하여 인삼을 발효시킬 경우 진세노사이드 Rg3 및 △20-진세노나이드 Rg3의 함량이 높은 인삼 발효물을 얻을 수 있다.The present invention also provides a method for producing ginseng fermentation comprising inoculating ginseng and incubating at least one strain selected from the group consisting of Lactobacillus plantarum KFCC11434P and Lactobacillus sakei KFCC11435P. To provide. As described above, Lactobacillus plantarum KFCC11434P and Lactobacillus sakei KFCC11435P newly isolated by the present invention have excellent saponin bioconversion ability, in particular, ginseng using When fermented, ginseng fermented with high content of ginsenoside Rg3 and Δ20-ginsenoide Rg3 can be obtained.
본 발명의 제조방법에서 상기 균주의 기질로서 사용하는 인삼은 특별히 한정된 것은 아니며, 인삼 그 자체 및 인삼 가공물을 모두 사용할 수 있으며, 예를 들어, 수삼, 홍삼, 홍미삼, 백삼, 미삼, 인삼 열매, 인삼 잎 등을 사용하거나 인삼 추출액 및 인삼 분말 등을 사용할 수 있다. 상기 인삼의 원산지는 제한되지 아니하며, 예를 들어 고려인삼, 삼칠인삼, 미국인삼, 죽절인삼, 히말라야인삼, 베트남인삼 등을 제한 없이 사용할 수 있다. 또한, 상기 인삼은 필요에 따라 통상의 방법으로 멸균시켜 사용할 수도 있다.The ginseng used as a substrate of the strain in the production method of the present invention is not particularly limited, and both ginseng itself and ginseng processed materials can be used, for example, ginseng, red ginseng, red rice ginseng, white ginseng, misam, ginseng fruit, ginseng Leaves and the like, or ginseng extract and ginseng powder may be used. The origin of the ginseng is not limited, and for example, Korean ginseng, samchil ginseng, American ginseng, bamboo shoot ginseng, Himalayan ginseng, Vietnamese ginseng and the like can be used without limitation. In addition, the ginseng may be used by sterilization in a conventional manner as needed.
또한, 대한민국 특허등록 제497,895호에서 개시하는 건조 분말 형태의 인삼, 산 처리 인삼, 고온처리 인삼 및 가압처리 인삼 등도 사용할 수도 있다. 그러나, 산 처리를 할 경우 배양액의 pH가 낮아져 균주의 활성이 낮아질 수 있으며, 고온으로 처리할 경우 열처리 과정에서 HMF 등의 발암물질이 생성될 수 있으므로, 인삼 또는 인삼 분말을 그대로 사용하는 것이 바람직하다. 상기 인삼 분말은 적어도 100 메쉬 이상의 입자크기를 갖는 분말이 인삼의 표면적을 증가시켜 미생물의 발효 속도를 높일 수 있다.In addition, ginseng in the form of a dry powder, acid treated ginseng, high temperature treated ginseng, and pressurized ginseng disclosed in Korean Patent Registration No. 497,895 may also be used. However, when the acid treatment is lowered the pH of the culture medium may lower the activity of the strain, and when treated at a high temperature may cause carcinogens such as HMF during heat treatment, it is preferable to use ginseng or ginseng powder as it is. . The ginseng powder may have a particle size of at least 100 mesh or more to increase the surface area of ginseng to increase the speed of fermentation of microorganisms.
인삼을 발효시키는 방법 즉, 균주의 접종 및 배양은 종래의 방법(대한민국 특허등록 제479,803호, 제497,895호, 제517,899호, 제618,171호 등)에 따라 수행할 수 있다. 예를 들어, 인삼 분말 또는 인삼의 추출액(예를 들어, 알콜 또는 알콜 수 용액 추출액, 열수 추출액 등)을 물에 현탁하여 상기한 균주를 넣고, 20 ∼ 50 ℃, 바람직하게는 30 ∼ 37 ℃에서, 12 시간 ∼ 15 일, 바람직하게 24 시간 ∼ 5 일 동안 배양함으로써 수행할 수 있다.The method of fermenting ginseng, that is, inoculation and culture of the strain may be performed according to conventional methods (Korean Patent Registration Nos. 479,803, 497,895, 517,899, 618,171, etc.). For example, ginseng powder or ginseng extract (for example, alcohol or alcohol solution extract, hot water extract, etc.) is suspended in water, and the above strain is added thereto, and at 20 to 50 ° C., preferably at 30 to 37 ° C. , 12 hours to 15 days, preferably 24 hours to 5 days.
상기와 같은 발효 과정을 거침으로써, 인삼 원재료에 함유된 진세노사이드 Rb1, Rb2, Rc, Rd 등이 진세노사이드 Rg3, △20-진세노사이드 Rg3, 화합물 K(Compound K), 진세노사이드 Rh2 등으로 생물전환된다.By going through the fermentation process as described above, ginsenosides Rb1, Rb2, Rc, and Rd contained in the ginseng raw material are ginsenosides Rg3, Δ20-ginsenoside Rg3, compound K (Compound K), ginsenoside Rh2 Bioconverted to the back.
본 발명의 제조방법은 상기 배양 후 얻어진 배양액을 80 ∼ 95 ℃에서 12 ∼ 48 시간 동안 숙성시키는 단계("숙성 단계")를 추가로 포함할 수 있다. 상기와 같은 조건에서 숙성 단계를 수행하게 되면, 숙성과 동시에 멸균도 함께 이루어지게 되며, 또한 진세노사이드 Rg3, △20-진세노사이드 Rg3 함량을 더욱 높일 수 있다.The production method of the present invention may further comprise the step of aging the culture solution obtained after the culture at 80 to 95 ℃ for 12 to 48 hours ("aging step"). When the aging step is performed under the above conditions, sterilization is also performed at the same time as aging, and further, ginsenoside Rg3 and Δ20-ginsenoside Rg3 may be further increased.
본 발명의 제조방법에 따라 얻어지는 인삼 발효물은 별도의 정제를 통하지 않고 직접 식품으로서의 사용이 가능하다. 즉, 본 발명의 제조방법에 따라 얻어진 인삼 발효물은 통상의 방법에 따라 농축시키거나 동결건조하여 분말화하여 그대로 식품에 적용할 수 있다. 즉, 숙성과정을 통하여 얻어진 숙성액을 농축 또는 동결건조한 것을 그대로 식품에 적용 수 있으며, 또는 상기 숙성액을 원심분리하여 취한 상등액을 농축 또는 동결건조하는 단계를 거쳐 얻어진 것을 그대로 식품에 적용할 수도 있다. The ginseng fermented product obtained according to the production method of the present invention can be used directly as a food without separate purification. That is, the ginseng fermented product obtained according to the production method of the present invention may be concentrated or lyophilized and powdered according to a conventional method and applied to food as it is. That is, the concentrated or lyophilized aging liquid obtained through the aging process may be applied to the food as it is, or the supernatant taken by centrifugation of the aging liquid may be applied to the food as it is. .
이하, 본 발명을 실시예를 통하여 더욱 상세히 설명한다. 그러나 이들 실시예는 본 발명을 예시하기 위한 것으로, 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to examples. However, these examples are for illustrating the present invention, and the scope of the present invention is not limited to these examples.
실시예 1. 균주의 분리 및 동정Example 1. Isolation and Identification of Strains
(1) 균주 분리(1) Strain Isolation
전국 각지로부터 수집한 분변 및 김치액을 4 ℃에 냉장보관하였다. 수집된 분변 및 김치액을 균일하게 교반한 다음, 0.9% 멸균생리식염수를 이용하여 단계적으로 희석하고(10-2, 10-4, 10-6 및 10-8), 유산균 분리용 배지인 MRS(deMan Rogosa Sharpe, Difco TM, Becton Dickinson and Company, USA)-BCP(Bromocresol Purple) 평판배지에 도말하였다. 도말한 배지는 30℃에서 집락의 형성을 관찰하였으며, 유의한 수준의 집락이 형성될 때까지 24-48시간 동안 배양하였다. 단일 집락으로서 구분 가능한 수준의 희석 농도의 배지에서 원래 배지의 색인 보라색이 균주의 젖산 형성을 통해 노란색의 집락 및 경계를 형성하는 균주 집락을 선별하였다. 선택된 집락들을 다시 MRS-BCP 평판 배지에 계대배양하여 단일 집락임을 다시 확인하고, 단일 집락으로 확인된 균주들에 대해서 대사 활성을 측정하였다.Fecal and kimchi collected from all over the country were refrigerated at 4 ℃. The collected fecal and kimchi solution was stirred uniformly, and then diluted stepwise using 0.9% sterile saline solution (10 -2 , 10 -4 , 10 -6 and 10 -8 ), and MRS (lactic acid bacteria separation medium) ( deMan Rogosa Sharpe, Difco ™, Becton Dickinson and Company, USA) -BCP (Bromocresol Purple) flat plates. The smeared medium observed colony formation at 30 ° C. and incubated for 24-48 hours until significant levels of colony were formed. Strain colonies were selected in which the index purple of the original medium formed yellow colonies and borders through the lactic acid formation of the strains in the media at diluent concentrations that were distinguishable as single colonies. Selected colonies were subcultured on MRS-BCP plate medium again to confirm that they were single colonies, and metabolic activity was measured for the strains identified as single colonies.
상기 활성은 얻어진 균주들을 홍삼 농축액에 가하여 대사 활성을 갖는지 여부를 확인함으로써 수행하였으며, 구체적으로는 홍삼농축액(충남 금산소재의 덕원인삼약초영농조합) 1㎖를 취한 후 0.9% 식염수로 적절하게 연속 희석한 다음 MRS 한천(agar)(Difco Laboratories, 덱스트로오즈 20.0g/ℓ; 미트 펩톤(meat peptone) 10.0g/ℓ; 비프 추출물(beef extract) 10.0g/ℓ; 효모 추출물 5.0g/ℓ; 소듐 아세테이트 5.0g/ℓ; 디소듐 포스페이트 2.0g/ℓ; 암모늄 시트레이트 2.0g/ℓ; 트윈 80 1.0g/ℓ; 마그네슘 설페이트 0.1g/ℓ; 망간 설페이트 0.05g/ℓ; 아가(agar) 15g/ ℓ)에 도말한 후 30℃와 37℃에서 72시간과 48시간 동안 각각 배양하였다. The activity was performed by adding the obtained strains to the red ginseng concentrate to check whether they had metabolic activity. Specifically, 1 ml of red ginseng concentrate (Deokwon ginseng herbal farming combination of Geumsan, Chungnam) was appropriately diluted with 0.9% saline. MRS agar (Difco Laboratories, dextrose 20.0 g / l; meat peptone 10.0 g / l; beep extract 10.0 g / l; yeast extract 5.0 g / l; sodium acetate 5.0 g / l; 2.0 g / l disodium phosphate; 2.0 g / l ammonium citrate; 1.0 g / l tween 80; 0.1 g / l magnesium sulfate; 0.05 g / l manganese sulfate; 15 g / l agar) After incubation at 30 ℃ and 37 ℃ was incubated for 72 hours and 48 hours, respectively.
상기와 같이 대사활성을 측정한 결과, 약 10종의 미생물을 분리하였다. 각각 분리된 미생물을 이용하여 홍삼추출물 10g에 물 90㎖를 가하고, 85 ℃ 에서 멸균한 다음, 미생물을 약 5 %의 농도로 접종한 후, 37 ℃에서 2일 동안 배양하였다. 얻어진 배양액을 85℃에서 24 시간 동안 숙성 및 멸균 처리한 다음, HPLC로 진세노사이드를 분석한 결과, 진세노사이드 Rg3 및 △20-진세노나이드 Rg3 생성능이 특히 높은 미생물 2종(CKDHC 0801 및 CKDHC 0802)을 선별하였다. 상기 미생물 2종 중, CKDHC 0801은 사람의 장내에서 분리된 균주이고, CKDHC 0802는 김치액에서 분리된 균주이다.As a result of measuring the metabolic activity as described above, about 10 kinds of microorganisms were isolated. 90 g of water was added to 10 g of red ginseng extract using each microorganism isolated, sterilized at 85 ° C., and then inoculated with the microorganism at a concentration of about 5%, followed by incubation at 37 ° C. for 2 days. The obtained culture was aged and sterilized at 85 ° C. for 24 hours, and then analyzed by ginsenoside by HPLC. As a result, two microorganisms (CKDHC 0801 and CKDHC) having particularly high ability to produce ginsenoside Rg3 and Δ20-gingenide Rg3 were detected. 0802). Of the two microorganisms, CKDHC 0801 is a strain isolated in human intestine, CKDHC 0802 is a strain isolated from kimchi liquid.
(2) 16S rRNA 유전자 염기 서열 분석에 의한 분리 균주의 동정(2) Identification of isolated strain by 16S rRNA gene sequencing
분리된 2종의 미생물의 16S rRNA 유전자 서열 분석을 수행하였다. 16S rRNA 유전자 서열 분석은, Lane, D. J. (1991), 16S/23S sequencing. In: Nucleic Acids Techniques in Bacterial Systematics, Eds.: Stackebrandt, E. and Goodfellow, M. pp. 115-175, John Wiley and Sons, New York 및 Harju, S., et al., 2004, Rapid isolation of yeast genomic DNA: Bust n' Grab. BMC Biotech. 21:4-8에 개시된 방법에 따라 실시하였다.16S rRNA gene sequencing of two isolated microorganisms was performed. 16S rRNA gene sequencing, see Lane, D. J. (1991), 16S / 23S sequencing. In: Nucleic Acids Techniques in Bacterial Systematics, Eds .: Stackebrandt, E. and Goodfellow, M. pp. 115-175, John Wiley and Sons, New York and Harju, S., et al., 2004, Rapid isolation of yeast genomic DNA: Bust n 'Grab. BMC Biotech. It was carried out according to the method disclosed in 21: 4-8.
상기 2종의 미생물을 MRS 액체 배지 10 ㎖에 접종하고 회전식 배양기 내에서 80 rpm, 30℃에서 2일간 배양하였다. 상기 배양액 1 ㎖을 1.5 ㎖ 원심분리 튜브에 넣고 15,000 x g로 5분간 원심분리하였다. 게놈 DNA를 추출하기 위해서 상층액을 제거한 후 튜브에 라이시스 완충액(2 %(v/v) Triton X-100, 1%(w/v) SDS, 100 mM NaCl, 10 mM Tris-Cl 및 1 mM EDTA; pH 8.0) 200 ㎕를 첨가하여 균질한 상태로 만든 뒤, 상기 튜브를 -80 ℃에서 4분간 얼리고, 곧이어 끓는 물에서 다시 2분간 중탕하였다. 이렇게 얼리고 녹이는 과정을 두 차례 수행한 뒤, 30초간 볼텍싱하였다. 그리고 200 ㎕의 클로로포름을 넣고 다시 2분간 볼텍싱한 뒤, 4℃에서 15,000 x g로 5분간 원심분리하였다. 상층액만 분리하여 2 ㎕의 RNaseI 용액(mg/ml)을 처리한 후 에탄올 침전법을 이용하여 게놈 DNA를 분리하고 TE 용액 200 ㎕에 용해하고, 이를 16S rRNA 유전자를 증폭하는 데에 사용하였다.The two microorganisms were inoculated in 10 ml of MRS liquid medium and incubated in a rotary incubator at 80 rpm and 30 ° C. for 2 days. 1 ml of the culture was placed in a 1.5 ml centrifuge tube and centrifuged at 15,000 x g for 5 minutes. The supernatant was removed to extract genomic DNA and then the tube was placed in Lysis buffer (2% (v / v) Triton X-100, 1% (w / v) SDS, 100 mM NaCl, 10 mM Tris-Cl and 1 mM). EDTA; pH 8.0) 200 μl was added to make it homogeneous, and the tube was frozen at −80 ° C. for 4 minutes and then bathed again in boiling water for 2 minutes. This freezing and melting process was performed twice, followed by vortexing for 30 seconds. Then, 200 μl of chloroform was added and vortexed again for 2 minutes, and then centrifuged at 15,000 × g for 5 minutes at 4 ° C. Only the supernatant was separated and treated with 2 μl of RNaseI solution (mg / ml). Genomic DNA was isolated using ethanol precipitation and dissolved in 200 μl of TE solution, which was used to amplify the 16S rRNA gene.
상기 미생물의 염색체 DNA로부터 16S rRNA 유전자를 프라이머 8F(AGAGTTTGATCCTGGCTCAG, 서열번호 3)와 1541R(AAGGAGGTGATCCAGCC, 서열번호 4)을 사용하여 PCR 증폭하였다. 증폭을 위한 PCR 프로그램은 다음과 같이 수행하였다. 94℃에서 5분 동안 반응시킨 다음 94℃에서 30초, 55℃에서 40초 및 72℃에서 1분 30초로 이루어진 사이클을 35회 반복하고 최종 신장 단계로서 72℃에서 5분간 반응시켰다. 게놈 DNA로부터 증폭된 PCR 산물을 Accu Prep gel 정제 키트(Accu. Chem. Sci. Corp. Westbury, N.Y.)를 사용하여 정제하였다. 이렇게 얻어진 각각의 PCR 증폭 산물을 각각 pPCR2.1-TOPO 벡터(Invitrogen, USA)에 도입하고 이 벡터를 이용하여 E. coli DH5a(Real Biotech, Inc., Taiwan)를 형질전환하였다. 유효한 E. coli DH5a 균주를 확인한 후 여기에서 플라스미드를 분리 정제하였다. 이렇게 해서 얻어진 플라스미드인 pM-2 및 pM-3에 있는 16S rRNA의 시퀀싱을 실시하였다. 서열분석 결과, 상기 2종의 미생물, 즉 CKDHC 0801 및 CKDHC 0802의 16S rRNA 서열은 각각 서열번호 1 및 2로 확인되었다(각각 1474 bp 및 1455 bp). 상기 유전자 서열을 BLAST를 사용하여 상동성을 분석한 결과, CKDHC 0801 균주는 락토바실러스 플란타럼(Lactobacillus plantarum)에 속하고, CKDHC 0802 균주는 락토바실러스 사케이(Lactobacillus sakei)에 속하는 새로운 균주로 판명되었다.16S rRNA gene from the chromosomal DNA of the microorganism was PCR amplified using primers 8F (AGAGTTTGATCCTGGCTCAG, SEQ ID NO: 3) and 1541R (AAGGAGGTGATCCAGCC, SEQ ID NO: 4). PCR program for amplification was performed as follows. After reacting at 94 ° C. for 5 minutes, the cycle consisting of 30 seconds at 94 ° C., 40 seconds at 55 ° C., and 1 minute 30 seconds at 72 ° C. was repeated 35 times and reacted at 72 ° C. for 5 minutes as the final elongation step. PCR products amplified from genomic DNA were purified using Accu Prep gel purification kit (Accu. Chem. Sci. Corp. Westbury, NY). Each PCR amplification product thus obtained was introduced into a pPCR2.1-TOPO vector (Invitrogen, USA) and transformed with E. coli DH5a (Real Biotech, Inc., Taiwan) using this vector. After valid E. coli DH5a strains were identified, the plasmids were isolated and purified. The sequencing of the 16S rRNAs in pM-2 and pM-3 which were thus obtained plasmids was performed. As a result of sequencing, the 16S rRNA sequences of the two microorganisms, CKDHC 0801 and CKDHC 0802, were identified as SEQ ID NOs: 1 and 2, respectively (1474 bp and 1455 bp, respectively). As a result of analyzing the homology of the gene sequence using BLAST, the CKDHC 0801 strain belongs to Lactobacillus plantarum , and the CKDHC 0802 strain turns out to be a new strain belonging to Lactobacillus sakei . It became.
(3) 당 발효능 분석(생화학적 특성 규명)(3) Analysis of sugar fermentation ability (biochemical characterization)
16S rRNA 유전자의 염기서열 분석을 통하여 얻어진 2 종의 미생물, 즉 락토바실러스 플란타럼(Lactobacillus plantarum) CKDHC 0801 및 락토바실러스 사케이(Lactobacillus sakei) CKDHC 0802 균주에 대하여, API 50 CHL 키트(BioMerieux, France)를 이용하여 49종의 당에 대한 발효 검사를 실시하였고, 그 결과는 표 1a 및 1b와 같다. For two microorganisms obtained through sequencing of the 16S rRNA gene, namely, Lactobacillus plantarum CKDHC 0801 and Lactobacillus sakei CKDHC 0802 strains, the API 50 CHL kit (BioMerieux, France) The fermentation test was carried out for 49 sugars using), the results are shown in Table 1a and 1b.
CKDHC 0801 Lb. plantarum
CKDHC 0801
CKDHC 0802 Lb. sakei
CKDHC 0802
CKDHC 0801 Lb. plantarum
CKDHC 0801
CKDHC 0802 Lb. sakei
CKDHC 0802
상기 표 1a 및 1b에서 "+"는 당을 이용하여 발효한 것, “-”는 해당하는 당을 이용하여 발효하지 못한 것을 나타낸다.In Tables 1a and 1b, "+" indicates fermentation using sugars and "-" indicates no fermentation using the corresponding sugars.
(4) 균주기탁(4) Strain Deposit
상기에서 분리된 2 종의 균주 즉, 락토바실러스 플란타럼(Lactobacillus plantarum) CKDHC 0801 및 락토바실러스 사케이(Lactobacillus sakei) CKDHC 0802 를 한국미생물보존센터에 2008년 12월 18일자로 기탁하고, 기탁번호 KFCC 11434P 및 KFCC 11435P를 부여받았다.The two strains isolated above, namely Lactobacillus plantarum CKDHC 0801 and Lactobacillus sakei CKDHC 0802, were deposited at the Korea Microorganism Conservation Center on Dec. 18, 2008, and deposited no. KFCC 11434P and KFCC 11435P were given.
실시예 2. Example 2.
고려 인삼 분말 50g에 물 250ml를 가하고, 85 ℃ 에서 멸균한 다음, 락토바실러스 플란타럼(Lactobacillus plantarum) CKDHC 0801(미생물 기탁번호 KFCC11434P)를 약 5 %의 농도로 접종한 후, 37 ℃에서 2일 동안 교반하면서 배양하였다. 이때, 상기 배양은 인삼 분말의 입자 공극에 배양액을 용이하게 확산시키기 위하여 감압하에서 실시하였다. 얻어진 배양액을 85℃에서 24 시간 동안 숙성 및 멸균처리하였다. 얻어진 숙성액을 75 ℃에서 진공 농축하여 인삼 발효물(즉, 발효인삼)을 제조하였다. 250 g of water was added to 50 g of Korean ginseng powder, sterilized at 85 ° C., and then inoculated with Lactobacillus plantarum CKDHC 0801 (microbial accession number KFCC11434P) at a concentration of about 5%, followed by 2 days at 37 ° C. Incubate with stirring. At this time, the culture was carried out under reduced pressure to easily diffuse the culture solution into the particle pores of ginseng powder. The resulting culture was aged and sterilized at 85 ° C. for 24 hours. The obtained aging solution was concentrated in vacuo at 75 ° C. to prepare ginseng fermented product (ie, fermented ginseng).
실시예 3. Example 3.
고려인삼 대신 미국인삼을 사용하고, 균주로서 락토바실러스 사케이(Lactobacillus sakei) CKDHC 0802(미생물 기탁번호 KFCC11435P)을 사용하여, 실시예 2와 동일한 방법으로 발효인삼을 제조하였다.American ginseng was used instead of Korean ginseng, and fermented ginseng was prepared in the same manner as in Example 2 using Lactobacillus sakei CKDHC 0802 (Microbial Accession No. KFCC11435P) as a strain.
실시예 4. Example 4.
고려인삼 대신 죽절인삼을 사용하고, 균주로서 락토바실러스 사케이(Lactobacillus sakei) CKDHC 0802(미생물 기탁번호 KFCC11435P)을 사용하여, 실시예 2와 동일한 방법으로 발효인삼을 제조하였다.Bamboo ginseng was used instead of Korean ginseng, and fermented ginseng was prepared in the same manner as in Example 2 using Lactobacillus sakei CKDHC 0802 (Microbial Accession No. KFCC11435P) as a strain.
실시예 5. Example 5.
고려인삼 대신 히말라야 인삼을 사용하여, 실시예 2와 동일한 방법으로 발효인삼을 제조하였다.Fermented ginseng was prepared in the same manner as in Example 2, using Himalayan ginseng instead of Korean ginseng.
실시예 6. Example 6.
고려인삼 대신 베트남 인삼을 사용하여, 실시예 2와 동일한 방법으로 발효인삼을 제조하였다.Using ginseng instead of Korean ginseng, fermented ginseng was prepared in the same manner as in Example 2.
시험예 1. Test Example 1.
비교예로서 대한민국 특허등록 제479,803호에 개시된 바에 따라, 발효인삼을 제조하였다(비교예 1). 상기 실시예 및 비교예에서 얻어진 발효인삼의 성분변화를 다음과 같이 측정하였다. 얻어진 인삼 발효물 5 g을 정밀히 달아 100 ㎖의 농축플라스크에 취하고, 감압농축 후 수포화 부탄올 50ml를 가하여 환류 냉각기를 붙여 수욕 중에서 70 ∼ 80℃로 약 1시간 가열 추출한 다음 냉각한 후 여과하고 잔류물에 대하여 같은 조작을 계속 2회 반복하였다. 여지는 수포화 부탄올 10 로 세척하고 여액 및 세척액을 합하여 250㎖ 분액깔때기에 넣고 물 20 ㎖로 잘 진탕시켜 수세하였다. 수포화 부탄올 추출액 전액을 미리 항량으로 한 농축플라스크에 옮겨 수욕 중에서 감압 농축하여 부탄올을 제거한 다음 그 잔류물에 에테르 50 ㎖를 넣고 환류냉각기를 붙여 수욕 중에서 36℃로 30분간 가열하여 탈지시킨 후 에테르를 제거하였다. 얻어진 잔류물에 10배의 메탄올을 가하여 완전히 용해한 다음 필터(0.45 ㎛)를 사용하여 여과한 다음 고속액체크로마토그래피(HPLC)로 진세노사이드 성분을 정량분석하였으며, 그 결과는 다음 표 2와 같다. 상기 HPLC 조건은 다음과 같다.As a comparative example, fermented ginseng was prepared as disclosed in Korean Patent Registration No. 479,803 (Comparative Example 1). The changes in the components of the fermented ginseng obtained in the above Examples and Comparative Examples were measured as follows. 5 g of the ginseng fermentation product obtained is precisely weighed and taken into a 100 ml concentrated flask. After concentration under reduced pressure, 50 ml of saturated butanol is added, a reflux condenser is added and the mixture is heated and extracted at 70 to 80 ° C. in a water bath for about 1 hour, and then filtered and the residue The same operation was repeated twice for. The filtrate was washed with saturated butanol 10 and the combined filtrate and washings were placed in a 250 ml separatory funnel and shaken well with 20 ml of water and washed with water. Transfer the entire saturated butanol extract to a concentrated flask with a constant amount, remove it under reduced pressure in a water bath, remove 50 mL of butanol, add 50 ml of ether to the residue, attach it to a reflux condenser, heat it for 30 minutes in a water bath, and degrease the ether. Removed. 10 times methanol was added to the obtained residue to completely dissolve it, and then filtered using a filter (0.45 μm), followed by quantitative analysis of ginsenoside components by high performance liquid chromatography (HPLC). The results are shown in Table 2 below. The HPLC conditions are as follows.
기구 : Shimadzu ProminenceOrganization: Shimadzu Prominence
칼럼 : Gromsil ODS 4.6(i, d) × 250mm Column: Gromsil ODS 4.6 (i, d) × 250 mm
이동상 A: 아세토니트릴:증류수=15:85Mobile phase A: acetonitrile: distilled water = 15: 85
이동상 B: 아세토니트릴:증류수=80:20Mobile phase B: acetonitrile: distilled water = 80: 20
유속 : 1.0 ㎖/minFlow rate: 1.0 ml / min
검출기 : ELSD(Alltech)Detector: ELSD (Alltech)
상기 표 2의 결과로부터 확인할 수 있는 바와 같이, 종래의 산처리 및 유산균 발효를 거쳐 제조한 발효 인삼의 경우, 진세노사이드 Rg3 및 △20-진세노사이드 Rg3 함량이 약 10% 내외에 불과하였으나, 본 발명에 따라 새롭게 분리된 균주를 사용하여 제조한 인삼 발효물은 진세노사이드 Rg3 및 △20-진세노사이드 Rg3 함량이 약 30% 이상의 높은 수준을 나타내었다.As can be seen from the results of Table 2, in the case of fermented ginseng prepared through conventional acid treatment and lactic acid bacteria fermentation, ginsenoside Rg3 and Δ20-ginsenoside Rg3 content was only about 10%, The ginseng fermentation product prepared using the newly isolated strain according to the present invention showed high levels of ginsenoside Rg3 and Δ20-ginsenoside Rg3 of about 30% or more.
<110> CHONGKUNDANGHEALTHCARE CO. <120> Korean intestine-derived microorganisms having saponin-biotransforming activity and processes for preparing fermented ginseng using the same <130> PN0240 <160> 4 <170> KopatentIn 1.71 <210> 1 <211> 1474 <212> DNA <213> Lactobacillus plantarum <400> 1 gcggttacgg cgtgctatac atgcaagtcg aacgaactct ggtattgatt ggtgcttgca 60 tcatgattta catttgagtg agtggcgaac tggtgagtaa cacgtgggaa acctgcccag 120 aagcggggga taacacctgg aaacagatgc taataccgca taacaacttg gaccgcatgg 180 tccgagcttg aaagatggct tcggctatca cttttggatg gtcccgcggc gtattagcta 240 gatggtgggg taacggctca ccatggcaat gatacgtagc cgacctgaga gggtaatcgg 300 ccacattggg actgagacac ggcccaaact cctacgggag gcagcagtag ggaatcttcc 360 acaatggacg aaagtctgat ggagcaacgc cgcgtgagtg aagaagggtt tcggctcgta 420 aaactctgtt gttaaagaag aacatatctg agagtaactg ttcaggtatt gacggtattt 480 aaccagaaag ccacggctaa ctacgtgcca gcagccgcgg taatacgtag gtggcaagcg 540 ttgtccggat ttattgggcg taaagcgagc gcaggcggtt ttttaagtct gatgtgaaag 600 ccttcggctc aaccgaagaa gtgcatcgga aactgggaaa cttgagtgca gaagaggaca 660 gtggaactcc atgtgtagcg gtgaaatgcg tagatatatg gaagaacacc agtggcgaag 720 gcggctgtct ggtctgtaac tgacgctgag gctcgaaagt atgggtagca aacaggatta 780 gataccctgg tagtccatac cgtaaacgat gaatgctaag tgttggaggg tttccgccct 840 tcagtgctgc agctaacgca ttaagcattc cgcctgggga gtacggccgc aaggctgaaa 900 ctcaaaggaa ttgacggggg cccgcacaag cggtggagca tgtggtttaa ttcgaagcta 960 cgcgaagaac cttaccaggt cttgacatac tatgcaaatc taagagatta gacgttccct 1020 tcggggacat ggatacaggt ggtgcatggt tgtcgtcagc tcgtgtcgtg agatgttggg 1080 ttaagtcccg caacgagcgc aacccttatt atcagttgcc agcattaagt tgggcactct 1140 ggtgagactg ccggtgacaa accggaggaa ggtggggatg acgtcaaatc atcatgcccc 1200 ttatgacctg ggctacacac gtgctacaat ggatggtaca acgagttgcg aactcgcgag 1260 agtaagctaa tctcttaaag ccattctcag ttcggattgt aggctgcaac tcgcctacat 1320 gaagtcggaa tcgctagtaa tcgcggatca gcatgccgcg gtgaatacgt tcccgggcct 1380 tgtacacacc gcccgtcaca ccatgagagt ttgtaacacc caaagtcggt ggggtaacct 1440 tttaggaacc agccgcctaa ggtgacaatg atgg 1474 <210> 2 <211> 1455 <212> DNA <213> Lactobacillus sakei <400> 2 agtcgaacgc actctcgttt agattgaagg agcttgctcc tgattgataa acatttgagt 60 gagtggcgga cgggtgagta acacgtgggt aacctgccct aaagtggggg ataacatttg 120 gaaacagatg ctaataccgc ataaaaccta acaccgcatg gtgtagggtt gaaagatggt 180 ttcggctatc actttaggat ggacccgcgg tgcattagtt agttggtgag gtaaaggctc 240 accaagaccg tgatgcatag ccgacctgag agggtaatcg gccacactgg gactgagaca 300 cggcccagac tcctacggga ggcagcagta gggaatcttc cacaatggac gaaagtctga 360 tggagcaacg ccgcgtgagt gaagaaggtt ttcggatcgt aaaactctgt tgttggagaa 420 gaatgtatct gatagtaact gatcaggtag tgacggtatc caaccagaaa gccacggcta 480 actacgtgcc agcagccgcg gtaatacgta ggtggcaagc gttgtccgga tttattgggc 540 gtaaagcgag cgcaggcggt ttcttaagtc tgatgtgaaa gccttcggct caaccgaaga 600 agtgcatcgg aaactgggaa acttgagtgc agaagaggac agtggaactc catgtgtagc 660 ggtgaaatgc gtagatatat ggaagaacac cagtggcgaa ggcggctgtc tggtctgtaa 720 ctgacgctga ggctcgaaag catgggtagc aaacaggatt agataccctg gtagtccatg 780 ccgtaaacga tgagtgctag gtgttggagg gtttccgccc ttcagtgccg cagctaacgc 840 attaagcact ccgcctgggg agtacgaccg caaggttgaa actcaaagga attgacgggg 900 gcccgcacaa gcggtggagc atgtggttta attcgaagca acgcgaagaa ccttaccagg 960 tcttgacatc ctttgaccac tctagagata gagctttccc ttcggggaca aagtgacagg 1020 tggtgcatgg ttgtcgtcag ctcgtgtcgt gagatgttgg gttaagtccc gcaacgagcg 1080 caacccttat tactagttgc cagcatttag ttgggcactc tagtgagact gccggtgaca 1140 aaccggagga aggtggggac gacgtcaaat catcatgccc cttatgacct gggctacaca 1200 cgtgctacaa tggatggtac aacgagttgc gagaccgcga ggtttagcta atctcttaaa 1260 accattctca gttcggattg taggctgcaa ctcgcctaca tgaagccgga atcgctagta 1320 atcgcggatc agcatgccgc ggtgaatacg ttcccgggcc ttgtacacac cgcccgtcac 1380 accatgagag tttgtaacac ccaaagccgg tgaggtaacc cttcggggag ccagccgtct 1440 aagtgaacag atgca 1455 <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 3 agagtttgat cctggctcag 20 <210> 4 <211> 17 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 4 aaggaggtga tccagcc 17 <110> CHONGKUNDANGHEALTHCARE CO. <120> Korean intestine-derived microorganisms having saponin-biotransforming activity and processes for preparing fermented ginseng using the same <130> PN0240 <160> 4 <170> KopatentIn 1.71 <210> 1 <211> 1474 <212> DNA <213> Lactobacillus plantarum <400> 1 gcggttacgg cgtgctatac atgcaagtcg aacgaactct ggtattgatt ggtgcttgca 60 tcatgattta catttgagtg agtggcgaac tggtgagtaa cacgtgggaa acctgcccag 120 aagcggggga taacacctgg aaacagatgc taataccgca taacaacttg gaccgcatgg 180 tccgagcttg aaagatggct tcggctatca cttttggatg gtcccgcggc gtattagcta 240 gatggtgggg taacggctca ccatggcaat gatacgtagc cgacctgaga gggtaatcgg 300 ccacattggg actgagacac ggcccaaact cctacgggag gcagcagtag ggaatcttcc 360 acaatggacg aaagtctgat ggagcaacgc cgcgtgagtg aagaagggtt tcggctcgta 420 aaactctgtt gttaaagaag aacatatctg agagtaactg ttcaggtatt gacggtattt 480 aaccagaaag ccacggctaa ctacgtgcca gcagccgcgg taatacgtag gtggcaagcg 540 ttgtccggat ttattgggcg taaagcgagc gcaggcggtt ttttaagtct gatgtgaaag 600 ccttcggctc aaccgaagaa gtgcatcgga aactgggaaa cttgagtgca gaagaggaca 660 gtggaactcc atgtgtagcg gtgaaatgcg tagatatatg gaagaacacc agtggcgaag 720 gcggctgtct ggtctgtaac tgacgctgag gctcgaaagt atgggtagca aacaggatta 780 gataccctgg tagtccatac cgtaaacgat gaatgctaag tgttggaggg tttccgccct 840 tcagtgctgc agctaacgca ttaagcattc cgcctgggga gtacggccgc aaggctgaaa 900 ctcaaaggaa ttgacggggg cccgcacaag cggtggagca tgtggtttaa ttcgaagcta 960 cgcgaagaac cttaccaggt cttgacatac tatgcaaatc taagagatta gacgttccct 1020 tcggggacat ggatacaggt ggtgcatggt tgtcgtcagc tcgtgtcgtg agatgttggg 1080 ttaagtcccg caacgagcgc aacccttatt atcagttgcc agcattaagt tgggcactct 1140 ggtgagactg ccggtgacaa accggaggaa ggtggggatg acgtcaaatc atcatgcccc 1200 ttatgacctg ggctacacac gtgctacaat ggatggtaca acgagttgcg aactcgcgag 1260 agtaagctaa tctcttaaag ccattctcag ttcggattgt aggctgcaac tcgcctacat 1320 gaagtcggaa tcgctagtaa tcgcggatca gcatgccgcg gtgaatacgt tcccgggcct 1380 tgtacacacc gcccgtcaca ccatgagagt ttgtaacacc caaagtcggt ggggtaacct 1440 tttaggaacc agccgcctaa ggtgacaatg atgg 1474 <210> 2 <211> 1455 <212> DNA <213> Lactobacillus sakei <400> 2 agtcgaacgc actctcgttt agattgaagg agcttgctcc tgattgataa acatttgagt 60 gagtggcgga cgggtgagta acacgtgggt aacctgccct aaagtggggg ataacatttg 120 gaaacagatg ctaataccgc ataaaaccta acaccgcatg gtgtagggtt gaaagatggt 180 ttcggctatc actttaggat ggacccgcgg tgcattagtt agttggtgag gtaaaggctc 240 accaagaccg tgatgcatag ccgacctgag agggtaatcg gccacactgg gactgagaca 300 cggcccagac tcctacggga ggcagcagta gggaatcttc cacaatggac gaaagtctga 360 tggagcaacg ccgcgtgagt gaagaaggtt ttcggatcgt aaaactctgt tgttggagaa 420 gaatgtatct gatagtaact gatcaggtag tgacggtatc caaccagaaa gccacggcta 480 actacgtgcc agcagccgcg gtaatacgta ggtggcaagc gttgtccgga tttattgggc 540 gtaaagcgag cgcaggcggt ttcttaagtc tgatgtgaaa gccttcggct caaccgaaga 600 agtgcatcgg aaactgggaa acttgagtgc agaagaggac agtggaactc catgtgtagc 660 ggtgaaatgc gtagatatat ggaagaacac cagtggcgaa ggcggctgtc tggtctgtaa 720 ctgacgctga ggctcgaaag catgggtagc aaacaggatt agataccctg gtagtccatg 780 ccgtaaacga tgagtgctag gtgttggagg gtttccgccc ttcagtgccg cagctaacgc 840 attaagcact ccgcctgggg agtacgaccg caaggttgaa actcaaagga attgacgggg 900 gcccgcacaa gcggtggagc atgtggttta attcgaagca acgcgaagaa ccttaccagg 960 tcttgacatc ctttgaccac tctagagata gagctttccc ttcggggaca aagtgacagg 1020 tggtgcatgg ttgtcgtcag ctcgtgtcgt gagatgttgg gttaagtccc gcaacgagcg 1080 caacccttat tactagttgc cagcatttag ttgggcactc tagtgagact gccggtgaca 1140 aaccggagga aggtggggac gacgtcaaat catcatgccc cttatgacct gggctacaca 1200 cgtgctacaa tggatggtac aacgagttgc gagaccgcga ggtttagcta atctcttaaa 1260 accattctca gttcggattg taggctgcaa ctcgcctaca tgaagccgga atcgctagta 1320 atcgcggatc agcatgccgc ggtgaatacg ttcccgggcc ttgtacacac cgcccgtcac 1380 accatgagag tttgtaacac ccaaagccgg tgaggtaacc cttcggggag ccagccgtct 1440 aagtgaacag atgca 1455 <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 3 agagtttgat cctggctcag 20 <210> 4 <211> 17 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 4 aaggaggtga tccagcc 17
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090032163A KR100997998B1 (en) | 2009-04-14 | 2009-04-14 | Korean intestine-derived microorganisms having saponin-biotransforming activity and processes for preparing fermented ginseng using the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090032163A KR100997998B1 (en) | 2009-04-14 | 2009-04-14 | Korean intestine-derived microorganisms having saponin-biotransforming activity and processes for preparing fermented ginseng using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100113717A KR20100113717A (en) | 2010-10-22 |
KR100997998B1 true KR100997998B1 (en) | 2010-12-03 |
Family
ID=43133121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090032163A KR100997998B1 (en) | 2009-04-14 | 2009-04-14 | Korean intestine-derived microorganisms having saponin-biotransforming activity and processes for preparing fermented ginseng using the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100997998B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150092978A (en) | 2014-02-06 | 2015-08-17 | 종근당건강 주식회사 | Ginseng drink tube and Red Ginseng Extract Fermented Red Ginseng Extract mixed drink tube manufacturing method |
KR20180000757A (en) | 2016-06-23 | 2018-01-04 | 중부대학교 산학협력단 | Fermented ginseng composite using bio-conversion and method thereof |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101285681B1 (en) * | 2010-12-17 | 2013-07-11 | 성금수 | Saponin-biotransforming activity and processes for preparing fermented ginseng using the same |
KR101331171B1 (en) * | 2012-08-14 | 2013-11-26 | 재단법인 금산국제인삼약초연구소 | Fermented-red gingseng or fermented-gingseng containing increased gensenoside rd and methods for preparation of the same |
KR101406975B1 (en) * | 2012-09-19 | 2014-06-13 | 대상 주식회사 | A Novel Strain of Kimchi Lactic Acid Bacteria Having Ginsenoside Rg3 Enrichment Activity and Methods for Preparing Fermented Ginseng Using The Strain |
KR102122439B1 (en) * | 2013-10-31 | 2020-06-15 | 에스케이바이오랜드 주식회사 | fermented red ginseng concentrate having hepatoprotective activity and manufacturing method thereof |
CN103695275B (en) * | 2014-01-07 | 2014-12-17 | 威海环翠楼红参科技有限公司 | Method for preparing Korean-ginseng and sea cucumber wine |
KR101641284B1 (en) * | 2014-09-05 | 2016-07-22 | 경희대학교 산학협력단 | Methods for Preparing Fermented Ginseng or Red Ginseng Enriched Rg3(S) |
KR101647631B1 (en) * | 2014-10-23 | 2016-08-11 | 한국식품연구원 | Composition for ginsenoside bioconversion comprising Lactobacillus plantarum WIKIM18 |
KR101683478B1 (en) * | 2014-12-22 | 2016-12-08 | 재단법인 전주농생명소재연구원 | Method for producing fermented red ginseng with enhanced ginsenoside Rg3 content |
KR101892615B1 (en) * | 2016-11-22 | 2018-08-28 | 한국식품연구원 | Lactobacillus sakei 2-6-4 and its use |
KR102259131B1 (en) * | 2018-12-21 | 2021-06-01 | 종근당건강 주식회사 | The manufacturing method of fermented red ginseng extracts enhanced with ginsenoside compound K, Rd and Rd3 using β-glucosidase and lactic acid bacteria |
CN115969724A (en) * | 2023-02-20 | 2023-04-18 | 三蚁科技(广州)有限公司 | Composition for delaying skin aging and preparation method thereof |
-
2009
- 2009-04-14 KR KR1020090032163A patent/KR100997998B1/en active IP Right Grant
Non-Patent Citations (1)
Title |
---|
박민주, 석사학위논문, 인삼 사포닌 변환 기술을 이용한 기능성 식품 소재의 탐색, pp. 28. (2008) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150092978A (en) | 2014-02-06 | 2015-08-17 | 종근당건강 주식회사 | Ginseng drink tube and Red Ginseng Extract Fermented Red Ginseng Extract mixed drink tube manufacturing method |
KR20180000757A (en) | 2016-06-23 | 2018-01-04 | 중부대학교 산학협력단 | Fermented ginseng composite using bio-conversion and method thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20100113717A (en) | 2010-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100997998B1 (en) | Korean intestine-derived microorganisms having saponin-biotransforming activity and processes for preparing fermented ginseng using the same | |
KR100856790B1 (en) | Methods for Preparing Fermented Ginseng or Red Ginseng | |
KR101285681B1 (en) | Saponin-biotransforming activity and processes for preparing fermented ginseng using the same | |
KR101832387B1 (en) | Method for producing fermented korean cultivated wild ginseng with enhanced specific ginsenoside content using lactic acid bacteria | |
KR101822024B1 (en) | A method of preparation for fermented red ginseng concentrate having increased content of compound K using conversion by enzyme mixture and fermentation by lactic acid bacteria and the products containing fermented red ginseng concentrate manufactured thereof as effective factor | |
KR101671435B1 (en) | Strain having ginsenoside bioconversion activity and manufacturing method of fermented red ginseng extract using the same | |
KR100824285B1 (en) | Processes for preparing a saccharified ginseng and ginseng extracts | |
KR100935362B1 (en) | Methods for Preparing Fermented Ginseng or Red Ginseng | |
KR20130107940A (en) | Method of producing fermented red ginseng | |
KR101980450B1 (en) | Composition of active wild-cultivated ginseng having increased ginsenoside Rd and compound K, chlorgenic acid and quercetin, and preparation method thereof | |
KR20100074382A (en) | Fermented drinks of ginseng and preparation method thereof | |
KR101768963B1 (en) | Lactobacillus paracasei strain with biological conversion activity of saponin, fermented ginseng extracts and manufacturing method of fermented ginseng extracts | |
KR20200025586A (en) | Saponin-biotransforming activity and processes for preparing fermented sprout ginseng and sprout red ginseng using the same | |
KR102530797B1 (en) | A mixed composition of Bacillus licheniformis IDCK30 and Bacillus subtilis IDCK40 for functional chungkookjang and a production method chungkookjang containing mountain-cultivated ginseng by using it | |
KR101771488B1 (en) | Novel Bacillus coagulans NRR1207, fermented ginseng using the same and probiotic composition containing the same | |
KR101898513B1 (en) | Novel Bacillus subtilis 4-1-1 and method for fermented ginseng using the same | |
KR101473634B1 (en) | Novel Lactobacillus sp. strain in probioic activation and method of producing of fermented red ginseng using the same | |
KR101583573B1 (en) | Manufacturing method of red ginseng by multistage heating | |
KR101434740B1 (en) | Novel Lactobacillus yonginsis THK-V8 and method for lowering molecular weight in saponin | |
KR101253875B1 (en) | Leuconotoc mesenteroides YLB 8 Capable of Bioconversion of Ginsenoside | |
KR20220143231A (en) | Manufacturing methods of heat-killed strain powder oriented from phellinus linteus, heat-killed strain powder and uses thereof | |
KR100813997B1 (en) | Processes for preparing jinseng extracts | |
KR20210089022A (en) | Low molecular weight fermented red ginseng and the method for preparing the same | |
KR101971186B1 (en) | A method of preparation for fermented red ginseng concentrate having increased content of ginsenoside Rd using fermentation by Bifidobacterium animalis ssp. lactis HY8002 and Bifidobacterium adolescentis HY8502 mixture | |
KR101473635B1 (en) | Novel Lactobacillus sp. strain in probioic activation and method of producing of fermented red ginseng using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20131122 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20141008 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20151221 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20161117 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20171027 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20180928 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20191126 Year of fee payment: 10 |